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Infectious diseases significantly threaten many wildlife populations. Proposed treatments
often fail to consider resulting impacts on natural host defense mechanisms and ongoing
infection risks. We demonstrate the importance of prior knowledge of host defenses
by modeling outcomes of various treatment regimes on bat populations infected with
white-nose syndrome (WNS), a disease that has caused declines in multiple North
American species. Despite differences in species susceptibility to the causative fungus,
how hosts respond to and survive infection remains unclear. We explore three potential
host-defense mechanisms: upregulation of the responsive innate or adaptive immune
systems, and rapid evolution that enables evolutionary rescue. We demonstrate that
treatment can accelerate extirpation (relative to inaction) if hosts are defended by
responsive immunity; whereas, treatment can cause populations undergoing evolutionary
rescue to regain population viability faster. We conclude that successful treatment of
wildlife diseases must first consider how individuals respond to and survive infection.
Keywords: bat conservation, disease treatmentmodeling, fungal pathogen, wildlife disease, white nose syndrome,
wildlife disease management
INTRODUCTION
Infectious disease historically has not been considered a major cause of species’ extinction and,
therefore, disease management has thus far remained a low priority relative to other conservation
actions (Fisher et al., 2012; Pullin et al., 2013). Mounting evidence suggests, however, that the
influence of infectious disease on extinction risk has been largely underestimated and that the
coupled effects of anthropogenic forces on hosts and diseases will greatly contribute to our global
biodiversity crisis (Smith et al., 2009; McCallum, 2012). Human influences drastically alter the
ecological landscape in which pathogens and potential hosts interact (Burge et al., 2014), increasing
both host susceptibility to infection and pathogen virulence (Brearley et al., 2013; Becker et al.,
2015). Anthropogenic climate change and globalization have expanded the natural range of many
pathogens and/or their suite of host species, releasing them from co-evolutionary forces that may
have maintained lower-virulence strains (e.g., Brasier and Buck, 2001). Climate change is especially
consequential for fungal pathogens, which are becoming increasingly heat-tolerant and thus able to
infect previously protected endothermic animals (Robert and Casadevall, 2009; Garcia-Solache and
Casadevall, 2010). The unprecedented frequency of disease emergence (Harvell et al., 2002; Fisher
et al., 2012) and the strength of impacts on wild populations (Daszak et al., 2000), increasingly point
to the importance of successful mitigation of disease in species’ conservation.
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Advances in antibiotics, fungicides, and probiotics make
effective treatment of wildlife diseases more achievable than
ever. However, while lab experiments or short-term field trials
may produce promising results (e.g., Cornelison et al., 2014),
deployment of a given treatment strategy may have unforeseen
negative consequences on the host population, especially if host
response to the pathogen (or its removal) is not considered in
advance. Therefore, it is critical to fully evaluate host-pathogen
interactions prior to the deployment of a treatment strategy.
Species broadly mitigate pathogen exposure in two ways:
either through an immunological response at the individual
level or an evolutionary response at the population level (or
both). Immunological responses can be innate or adaptive,
and the activation of either can have different consequences
on the host. The innate immune system is often a first
line of defense, identifying invading pathogens using pattern
recognition receptors to set off signaling cascades (i.e., Toll
pathway, Lai et al., 2009) and result in general responses such
as inflammation and ingestion of pathogens by macrophages
(e.g., Rizzetto et al., 2013). The adaptive immune system
is more specialized, using antigen-specific cells to recognize
individual pathogens and memory cells to mount responses
upon repeated exposure (note this adaptation is individual not
evolutionary, Hebart et al., 2002; Romani, 2004). In contrast,
an evolutionary response acts at the population level, whereby
pathogen exposure causes steep demographic decline, inducing
an intense selective pressure that favors survival of individuals
with a specific genetic signature (i.e., resistance). A population
consisting of primarily resistant individuals could revert to
positive growth without human intervention, a phenomenon
known as evolutionary rescue (Gonzalez et al., 2013), but
may benefit from targeted treatment while at low population
size (Maslo and Fefferman, 2015). These stark differences in
potential disease-defensive mechanisms suggest the possibility
for equally significant differences in long-term population effects
of treatment. To demonstrate how overlooking these potential
differences can compromise conservation efforts, we consider
a currently unfolding case study: treatment of white-nose
syndrome (WNS) in North American bats.
In the 10 years following WNS emergence, the disease
has caused severe declines in several bat species in eastern
North America (Langwig et al., 2015a). The conservation
community has made significant strides in understanding this
previously unknown disease of bats, including identification
of the causative agent, Pseudogymnoascus destructans (Lorch
et al., 2011). P. destructans is non-native to North America
and appears to have been transported by humans from its
endemic range in Europe (Puechmaille et al., 2011). The fungus
colonizes bats during an immunosuppressed torpor, but while
European bats tolerate infection (Puechmaille et al., 2011), naïve
North American bats experience a disruption of physiological
homeostasis leading to measureable population declines (Willis
et al., 2011; Verant et al., 2014). Severity of these declines has
created a sense of urgency for conservation intervention in the
form of chemical or biological control (e.g., fungistatic volatile
organic compounds; Cornelison et al., 2014), probiotics (e.g.,
Cheng et al., 2016), or synthetic compounds (e.g., Raudabaugh
and Miller, 2015) to either prevent pathogen exposure to naïve
populations or reduce disease intensity in infected populations.
Population declines due to WNS vary among species (Frick
et al., 2015), and drivers of observed survival patterns remain
unclear. For example,Myotis lucifugus (little brown bat) survival
rebounded markedly in the years following disease emergence
(Maslo et al., 2015) suggesting a rapid evolutionary response
(Maslo and Fefferman, 2015). However, M. lucifugus exposed to
P. destructans also exhibit elevated expression of genes related
to the responsive innate immune system (Field et al., 2015). In
mammalian fungal infections, innate immunity is thought to be
particularly important in regulating infection and suppressing
memory T cells to avoid potentially damaging inflammation
(Bacher et al., 2014).
To explore treatment impacts on population recovery under
each of the possible disease-defense mechanisms, we applied
to an existing model set predicting WNS-infected population
dynamics (Maslo and Fefferman, 2015), a suite of antifungal
treatment regimes informed by the conservation community
(WNS workshop, July 2015). Scenarios varied in treatment
efficacy and the proportion of remnant populations treated.
For simplicity, we consider only the responsive innate immune
system, which is upregulated upon pathogen exposure, and not
the baseline innate immune system, which protects the host
indiscriminately and can be assumed to act equally in all of
the considered scenarios. We evaluate persistence time of the
population under each scenario, and determine the minimum
population size for populations undergoing an evolutionary
response. While these results may inform discussions of
treatment for WNS in bat populations, our broader goal is
to demonstrate the need for consideration of disease-defense
mechanisms at play in any infected population being considered
for treatment-based conservation actions.
METHODS
Host Response-Based Population Viability
Models
Maslo and Fefferman (2015) recently modeled the population
dynamics ofMyotis lucifugus undergoing responsive immunity or
evolutionary rescue in the face ofWNS (summarized below). The
evolutionary rescue model makes the conservative assumption
that phenotypic robustness to WNS was based upon a Boolean
protective genetic profile. Bats within an uninfected population
were either entirely robust, r, or susceptible, wt, to WNS-induced
mortality. Using published or estimated vital rates from before
(Mwt andMr) and after (
+
Mwt
and +Mr ) P. destructans introduction
(Frick et al., 2010b; Maslo et al., 2015), Maslo and Fefferman
(2015) parameterized four two-stage Lefkovitch matrices (Morris
and Doak, 2002), each representing population growth of one
genetic segment of the population in both the uninfected and
infected state:
[
Sj × Bj × Fj Sa × Ba × Fa
Sj Sa
]
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where S represents survival of M. lucifugus; B represents the
proportion of females breeding; and the subscripts j and a
indicate values for 1st-year or adult bats, respectively. They set
1st-year bat survival as a constant proportion (0.47) of adult
survival (Frick et al., 2010b), and held maternity (m) constant
at F = 1, as M. lucifugus typically produce a single pup per year
(Barclay et al., 2003).
Starting with an initial population vector of 5,000 total
individuals, they estimated initial prevalence of the robust
genetic profile in the population to be ρ0 and then split the
initial demography υ¯total, 0 into two corresponding initial vectors
υ¯wt, 0 and υ¯r, 0 such that υ¯r, 0 = ρ0υ¯total, 0 and υ¯wt, 0 =
(1− ρ0) υ¯total, 0. This approach deviated from traditional PVA,
which would apply a single population projection matrix
to a single state vector representing the current stage-based
demography of the population. Maslo and Fefferman (2015)
then projected population growth in the absence of disease by
independently applying the appropriate matrix to each vector
to obtain the population vector for the next year: Mwtυ¯wt, t =
υ¯wt, t+1 and Mrυ¯r, t = υ¯r, t+1. Maslo and Fefferman (2015) then
computed the realized total population vector υ¯wt, t+1 + υ¯r, t+1,
and resulting growth rate.
The model assumes environmental contamination for an
entire habitat (e.g., hibernaculum) with 100% infection following
contamination. They define It to be the percent of the population
infected in year t and assume that the rate of exposure/infection
in a hibernaculum is independent of genetic robustness. Using
these probabilities and matrices, they then computed the
subpopulations in year t + 1 within a single population as
the sum of individuals that are wild type and uninfected:
(1− It)Mwtυ¯wt, t , robust and uninfected: (1− It)Mrυ¯r,t , wild
type and infected: It
+
Mwt
υwt, t , and robust and infected: It
+
Mr
υr, t .
Additionally, 0.1% of the offspring from same profile pairs
spontaneously mutate to the other profile (i.e., wt × wt results
in a Robust offspring), and r × wt results in 50% of each profile.
Assuming random mating among adults Maslo and Fefferman
(2015) “corrected” each of the projected population vectors by
subtracting the offspring with different genetic profiles from the
projected population vector associated with the matrix relevant
for the parents, and adding them to the offspring in the vector
associated with the appropriate subpopulation for the resulting
juvenile.
Under evolutionary rescue, the resulting total population
vector in each year was the sum of the individuals within each
subpopulation, and the stabilized growth rate (λ = 1.05) was
representative of the shifting proportion of genetic robustness
within the population (Maslo and Fefferman, 2015). Under
responsive immunity, the model projected a single state vector
(N = 5000) representing pre-WNS stage-based demographic
structure through a single projection matrix (parameterized
with survival estimates generated from population counts of
multiple infected hibernacula within the first three years of WNS
emergence; Frick et al., 2010a). The model output predicted
continued population declines stabilizing at λ= 0.89 after 3 years.
For the current analysis, we separated the acquired immune
response into adaptive and innate immunity and used both
published and estimated vital rates. Both provide protection
against mortality for individuals that survived initial exposure,
but adaptive immunity confers life-long individual protection,
whereas the innate immune protection is lost in the absence
of continued pathogen exposure. Individuals with adaptive
immunity were therefore modeled in the same way as (Maslo and
Fefferman, 2015). In contrast, treated and re-exposed individuals
with innate immunity suffered the same initial mortality risks
from re-exposure as though they had never previously been
immune (though if they survived, they would again be protected
throughout the duration of their continuous exposure). In all
other ways, this population was also modeled as in Maslo and
Fefferman (2015) (Figure 1). Note that this representation of
innate immunity can vary either in dose-response curves, or in
physiological state of the individuals. However, we do assume
that rapidity of the innate response is not itself consistent for an
individual over time. We make this assumption because such a
consistent response would likely have a genetic component and
be considered a potential mechanism for evolutionary rescue,
thus covered by that scenario.
Treatment Regimes
We applied a suite of treatment regimes to the three host
response scenarios (Figure 2), making the following assumptions
based on current treatment research: (1) treatment application
occurs just prior to or during the hibernation period; (2) no
immigration/emigration occurs after treatment deployment; and
(3) treatment suppresses P. destructans growth for a single
hibernation season. In the pulsed model (Figure 2), bats are
treated in the 1st, 5th, and 10th year following WNS arrival. We
modeled constant treatment application regimes, beginning 5 or
15 years following WNS arrival at a site. We also examined the
impacts of an interval treatment regime, where bats are treated
annually between 5 and 15 years following WNS arrival. We
modeled the demographic impacts of each treatment regime for
treatments that were 25, 50, 75 or 100% effective and were applied
to 25, 50, 75 or 100% of the population. We assumed a quasi-
extinction threshold of 150 individuals, belowwhich a population
was considered extirpated. If a population reverted to positive
growth, we calculated the time required for the abundance to
reach its minimum viable population size (assumed to be 2,500
individuals based upon a review of finite rates of increase at
WNS-infected hibernacula of various sizes; Maslo and Fefferman,
2015).
RESULTS
Model results predict that populations exhibiting a responsive
immune reaction after initial pathogen exposure persist for
13 years without treatment application (Figure 3). Regardless
of treatment effectiveness or the proportion of the population
treated, all populations persist indefinitely when treatment is
applied annually beginning in Year 5 of a WNS epizootic. In
contrast, beginning treatment in Year 15 results in a persistence
time of only 13 years for populations exhibiting responsive
immunity.
Pulsed treatments result in expedited extirpation of
populations with immunity within 10–21 years, with more
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FIGURE 1 | Flow chart of the model under each scenario: (A) evolutionary rescue for wildtype individuals, (B) evolutionary rescue for robust individuals, (C)
adaptive immunity for all (wildtype) individuals, and (D) innate immunity for all (wildtype) individuals. Population vital rates (survival and reproduction) for juvenile and
adult little brown bats under each scenario are indicated below the flowchart.
Frontiers in Ecology and Evolution | www.frontiersin.org 4 April 2017 | Volume 5 | Article 28
Maslo et al. White Nose Syndrome Treatment Modeling
FIGURE 2 | Hypothetical treatment regimes for bat colonies infected
with white-nose syndrome. Pulsed treatments occur in the 1st, 5th, and
10th year following disease emergence. Constant 5 and Constant 15
treatments occur annually beginning in Years 5 and 15, respectively. Interval
treatments occur annually between the 5th and 15th year following disease
emergence.
effective treatments decreasing years of persistence, a particularly
strong trend for innate immunity scenarios. Interval treatments
increase the persistence time of populations with adaptive
immunity by two to 11 years when >50% of the population is
inoculated at treatment efficacies of ≥50%, and persistence time
generally increases with increasing treatment effectiveness and
proportion of population treated. However, interval treatments
of populations with innate immunity only drastically increase
persistence time when the entire population is treated with
≥75% efficacy.
At low treatment efficacies (25–50%), the proportion of the
population treated minimally impacts the resulting persistence
time of each treatment regime across all host responses.
As effectiveness increases, treating a large proportion (75–
100%) of the population can have appreciable positive or
negative impacts on persistence time, extending it for 21
years when an interval treatment is applied to a population
with adaptive immunity, or decreasing it to 4 years when
a pulsed treatment is applied to a population with innate
immunity.
All populations undergoing evolutionary rescue revert
to positive growth between 5 and 11 years after disease
emergence and persist indefinitely regardless of treatment
regime, effectiveness, or the proportion of population treated
(Figure 3). With no intervention, a population undergoing
evolutionary rescue reaches its lowest size of 626 individuals
in 10 years and is predicted to return to an abundance
of 2,500 individuals within 39 years. Implementing constant
annual treatments beginning in Year 15 reduces that timeframe
minimally (1–2 years) across all treatment efficacies, regardless of
the proportion of the population treated (Figure 4), and increases
the minimum population size only marginally to 686 individuals.
At low treatment efficacies (25–50%), the proportion of the
population treated does not drastically alter the time required
for a population to achieve its minimum viable population size
(1–8 years). However, treating at least 75% of the population
annually starting in Year 5, once every five years (pulsed), or in
Years 5–15 can increase the absolute minimum population size
by 35–84%. At 75–100% effectiveness, treating more individuals
in a population can significantly reduce the time required
for abundance to reach 2,500 individuals, particularly if the
treatment is applied annually beginning in Year 5 or between
Years 5–15. Treating 100% of the population with a 100%
FIGURE 3 | Persistence time for a hibernating bat population if 0, 25,
50, 75 or 100% of the population is treated with an agent that is 0, 25,
50, 75, and 100% effective. Results are shown for bats exhibiting: (A)
evolutionary rescue; (B) adaptive immunity; and (C) responsive innate
immunity. Dotted lines represent the years to which populations will persist if
no treatment is applied.
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FIGURE 4 | Bats undergoing evolutionary rescue under different treatment regimes display differences in the: (A) time until the population reaches its
minimum viable population size of 2,500 individuals; (B) proportion of resistant individuals within the population when it reaches its minimum viable population size; (C)
population size at its inflection point (just prior to reversion to positive growth); and (D) year after WNS in which the population reaches this minimum size.
effective treatment under these two scenarios can increase the
population to its minimum viable population size in as little as
nine years (Figure 4).
Importantly, the proportion of resistant bats within the
population of 2,500 individuals remains above 99% in all but four
cases. Annual treatment beginning in Year 5 of either all bats
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treated at 75% effectiveness or 75% of the bats treated with a 100%
effective agent reduces the proportion of resistant bats to 83%.
Treating all bats with a 100% effective agent annually beginning
in Year 5 or between Years 5 and 10 allows non-resistant bats
to persist, thus reducing the proportion of resistant bats to 31%
(Figure 4).
DISCUSSION
Implications for Bat Conservation
For bats undergoing either type of immune response, annual
treatment beginning early in the disease phase may be extremely
effective in reversing demographic decline and creating a positive
growth trajectory. However, long-term treatment of multiple
bat populations presents several logistical challenges. Treatments
applied directly to bats would require significant numbers of
individuals to be captured at least once each year (treatments
may not last a full hibernation season). Traditional bat capture
methods (e.g., harp traps, mist nests) may not guarantee
treatment of even 25% of the population in any given year.
Actively treating bats during the hibernation period would
increase the likelihood that the appropriate threshold number
of bats are treated but would disturb hibernating populations
unless a passive delivery system is implemented. Hibernaculum
treatments (e.g., antifungal treatment of surfaces, VOC treatment
of air) may offer a more practicable approach, but treating
every infected North American hibernaculum in perpetuity is
not sustainable. Identifying the appropriate treatment approach
becomes important when monetary and physical feasibility is
taken into account. Furthermore, different bat species may
be responding to the disease differently, understanding the
host response will help to prioritize treatment of species
and determine whether one treatment regime is appropriate
for all species or if individual treatment plans should be
developed.
Implications for All Treatment-Based
Conservation
Understanding a host’s response to a pathogen prior to
intervention is critical to success. While it is tempting to assume
that any decrease in pathogen load would be beneficial, the
physiology of natural immunity may not always allow such
black-and-white solutions. As we have shown, if individuals
upregulate physiologically costly innate immune protections
only during pathogen exposure and downregulate them once
the threat is passed, removal of the trigger for protection
can cause a protected population to revert to vulnerability.
In these cases, treatment in the absence of reasonable belief
that the pathogen will not be reintroduced until after the
population has recovered to pre-infection sizes (or beyond)
could be catastrophic. Of course, the disease in the absence of
treatment may itself be catastrophic. If the ongoing mortality
is sufficiently high to compromise the long-term population
growth rates, treatment may be the only option. In this case,
if innate immunity is providing protection, we must recognize
the risks of inconsistent treatment regimes and commit to
constant efforts. There is still a point of no return beyond which
even constant treatment cannot guarantee the persistence of
the population (e.g., small population paradigm, Allee effects,
etc.). If the only mechanisms of protection are from immunity
and not evolutionary rescue, treatment must begin early enough
to preserve a sufficient number of mostly healthy, breeding
individuals. Models of this sort will be a critical tool in evaluating
when this point-of-no return might happen, what level of
efficacy is required and what treatment regime will ensure
survival.
The prospects for a population are better under the processes
of evolutionary rescue even without intervention. In these cases,
treatment becomes a beneficial mechanism for support of the
population to mitigate the initial drop in population size as
infection decimates individuals without protective genotypes.
Increasing the survival of unprotected individuals can prevent
the population from growing too small, or being moderately low
for too long. However, treatment will also ease the intensity of the
selective pressure, slowing the rate of replacement of unprotected
individuals by protected individuals. The simulations presented
here assumed 50% probability of protection for the offspring
of mating between protected and unprotected individuals (i.e.,
a dominant trait on a single locus that assorts independently).
In reality, genetically-derived protection against infection is
likely due to a suite of genes that do not assort simply,
and dilution of selective pressure must therefore also be
considered.
Lastly, evolutionary rescue is not mutually exclusive with
either immune protection, meaning that the impact of treatment
on real-world population persistence will entail a complicated
trade-off between the dilution of selective forces, themitigation of
mortality costs from new infections due to ongoing transmission,
and the potential for compromising ongoing innate immune
protection in already-exposed individuals. By tailoring models
to reflect the genetic and immunological processes of particular
systems, we can begin to consider certain treatment strategies,
weighing these impacts explicitly, and discovering how best to
manage populations under threat.
The implications of these models extend beyond the WNS
epizootic. For the increasing numbers of emerging wildlife
diseases, such as the recently discovered snake fungal disease
(Tetzlaff et al., 2015) or the multiple etiologically complicated
coral diseases (Weil and Rogers, 2011; Sutherland et al., 2016),
our study underscores the importance of studying the host
response concurrently to investigating mechanisms of infection
and transmission. The fungus Batrachochytrium dendrobatidi has
caused worldwide declines in amphibian populations, leading
to coordinated efforts to control pathogen spread, understand
mechanisms of transmission and infection, and treat the disease
(Whilde et al., 2017). However, efforts to treat infection have been
largely unsuccessful and different species have varying degrees
of susceptibility (Heard et al., 2011; Woodhams et al., 2012).
Recent evidence shows that immunosuppression of the host by
the pathogen may play a critical role in its ability to infect hosts
(Savage et al., 2016) indicating that a better understanding of the
host response(s) will help to elucidate a successful treatment plan
for this disease. For more well-characterized diseases, such as
Dermo in oysters (Burge et al., 2014) or chronic wasting disease
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in cervids (Williams et al., 2002), where the host response may
be better understood, our study demonstrates the necessity of
incorporating what is known of the host response into an efficient
and effective treatment plan.
The implications of these models extend beyond the WNS
epizootic. For the increasing numbers of emerging wildlife
diseases, such as the recently discovered snake fungal disease
(Tetzlaff et al., 2015) or the multiple etiologically complicated
coral diseases (Weil and Rogers, 2011; Sutherland et al., 2016),
our study underscores the importance of studying the host
response concurrently to investigating mechanisms of infection
and transmission. The fungus Batrachochytrium dendrobatidi has
caused worldwide declines in amphibian populations, leading
to coordinated efforts to control pathogen spread, understand
mechanisms of transmission and infection, and treat the disease
(Whilde et al., 2017). However, efforts to treat infection have been
largely unsuccessful and different species have varying degrees
of susceptibility (Heard et al., 2011; Woodhams et al., 2012).
Recent evidence shows that immunosuppression of the host by
the pathogen may play a critical role in its ability to infect hosts
(Savage et al., 2016) indicating that a better understanding of the
host response(s) will help to elucidate a successful treatment plan
for this disease. For more well-characterized diseases, such as
Dermo in oysters (Burge et al., 2014) or chronic wasting disease
in cervids (Williams et al., 2002), where the host response may
be better understood, our study demonstrates the necessity of
incorporating what is known of the host response into an efficient
and effective treatment plan.
CONCLUSION
Wildlife disease treatments that show promise in the lab
still face significant hurdles before treatments can be applied
successfully to wild populations (Langwig et al., 2015b). Both
treatment efficacy in pathogen removal and the percent of
the host population that can be treated given economic and
logistic constraints contribute to these hurdles. However, beyond
these direct considerations of development and deployment,
our results clearly demonstrate the need to consider the
impact of treatment on the ongoing dynamics between host
defense mechanisms and disease dynamics before treatment-
based interventions can truly be added to our arsenal of
conservation tools.
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